Edwards Lifesciences Corporation (NYSE:EW) has a 1 Year Target Estimate of $122.1. The stock traded with the volume of 2.77 Million in the last trading session. Edwards Lifesciences Corporation opened at $84.56 and closed by showing a decrease of -0.47%. The Bid price in the last session was $83.50 x 100 and the Ask price was $84.00 x 800. (The ask price is what sellers are willing to take for it. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The difference (or spread) goes to the broker/specialist that handles the transaction).
Edwards Lifesciences Corporation has the Market Capitalization of 17.94 Billion. The Stock has its 52-week High of $121.75 and 52-Week Low of $72.2 and it touched its 52-week high on Oct 10, 2016 and 52-Week Low on Jan 20, 2016.
Edwards Lifesciences Corporation reported its last Earnings on Oct 25 AMC where the company reported Actual EPS of $0.68/Share whereas, the Analyst Estimated EPS was $0.68/share. The difference between Actual EPS and Estimated EPS was $0/share. This represented an Earnings Surprise of 0%. The company will report its next earnings on Jan 31 – Feb 6 (Est.).
20 number of analysts also provided their insight on Edwards Lifesciences Corporation, where the Average Price Target for the stock is $122.1. They also projected Low Price Target as $88 while High Price Target is set at $140.
A number of analysts rated the stock as well: 8 analysts believe that the stock is a STRONG BUY while 10 reported it as Buy.4 analysts assigned a HOLD rating, 0 said it’s UNDERPERFORM and 1 say that this stock is a SELL.
Edwards Lifesciences Corporation annual Divided is 0 while it’s Dividend Yield is 0%. The stock has its Price to Earnings (P/E) ratio of 33.18 and Forward Price to Earnings ratio of 24.62. The company has its Price to Sales (P/S) ratio of 6.26 where Price to Book (P/B) ratio of 6.64, Price to Cash Per share (P/C) of 14.95 and Price to Free Cash Flow (P/FCF) has a value of 43.58.
The company has its Return on Assets (ROA) of 13.5 Percent. Return on Equity (ROE) stands at 22.1% and Return on Investment (ROI) displays a value of 15.9%.
The stock is currently trading at Distance from 20-Day simple moving Average of -6.23% whereas, Distance from 50-Day Simple moving average is -20.48 Percent and Distance from 200-Day Simple Moving Average of -18.78 percent.
A look at performance overview of Edwards Lifesciences Corporation depicts that Performance (Week) is -5.94 percent while Performance Month is -12.75%. Quarterly performance shows a value of -27.25% and Half Year Performance value stands at -15.97%. Yearly performance of the stock has the value of 2.94 percent. Edwards Lifesciences Corporation has its YTD performance of 6.23 Percent. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging).
Many Insiders have done trades inside the company. The latest trade was made on 28 Aug 2016 where Chief Operating Officer Hoffman (Marc A) did a transaction type “Sell” in which 10000 shares were traded at a price of $13.92. Another insider trade includes Director Lewis (Thomas A Jr) who also initiated a transaction in which 25000 shares were traded on 16 Aug 2016 as “Sell”. On 14 Aug 2016 Chief Investment Officer Springer (Robert C) traded 32998 shares as “Sell” at $13.81. Director Russell (Keith P) Sell 10000 shares on 13 Jun 2016 at the price of $11.54.
The latest Upgrades/Downgrades was done by Research firm Northland Capital on 8-Nov-16 who Upgrade the stock from Market Perform to Outperform. Other firms have also Upgraded/Downgraded the stock. On 27-Jul-16, BofA/Merrill took an action “Upgrade” from Neutral to Buy. On 9-Jun-16, the stock was Initiated to Neutral by Guggenheim.